IL17A and cancer: In summary, our bi-specific inhibitor targeting MMP-9 and IL-17A can pave the way for the generation of additional bi-specific inhibitors targeting metalloproteinases and pro-inflammatory cytokines for targeting tumors in which the cross-talk between extracellular matrix remodeling and the immune system is a major driving force in cancer progression.